Страна: Малайзия
Език: английски
Източник: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
MELOXICAM
DYNAPHARM (M) SDN BHD
MELOXICAM
100x10'stablet Tablets; 10x10'stablet Tablets; 50x10'stablet Tablets; 1x10'stablet Tablets
DYNAPHARM (M) SDN BHD
DYNAPHARM (M) SDN BHD DYNA MELOXICAM TABLET 7.5MG MALxxyyzzzzA CONTENT PER TABLET Meloxicam 7.5 mg PRODUCT DESCRIPTION Yellow coloured, round, flat and double scored uncoated tablet. PHARMACODYNAMICS Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the enolic acid class which has shown anti-inflammatory, analgesic and antipyretic properties in animals. Meloxicam showed potent anti-inflammatory activity in all standard models of inflammation. A common mechanism for the above effects may exist in the ability of meloxicam to inhibit the biosynthesis of prostaglandins, known mediators of inflammation. Comparison of the ulcerogenic dose and the anti-inflammatory effective dose in the rat adjuvant arthritis confirmed a superior therapeutic margin in animals over standard NSAIDs. In vivo, meloxicam inhibited prostaglandin biosynthesis more potently at the site of inflammation than in the gastric mucosa or the kidney. PHARMACOKINETICS Absorption Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute bioavailability of 89% following oral administration. Following single dose administration of meloxicam, mean maximum plasma concentrations are achieved within 2 hours for the suspension and within 5- 6 hours with solid oral dosage forms. With multiple dosing, steady state conditions were reached within 3 to 5 days. Once daily dosing leads to drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4 - 1.0µg/mL for 7.5mg doses and 0.8 - 2.0µg/mL for 15mg doses, respectively (Cmin and Cmax at steady state, respectively). Maximum plasma concentrations of meloxicam at steady state, are achieved within five to six hours for the tablet, capsule and the oral suspension, respectively. Continuous treatment for longer periods (e.g. six months) did not point to any changes in pharmacokinetics compared to steady state pharmacokinetics after two weeks of oral treatment with 15 mg meloxicam/day. Any differences after treatment longer than six mo Прочетете целия документ